ライフサイエンスコーパス: weakness

1 contributor to intensive care unit acquired weakness.

2 atory distress syndrome survivors had muscle weakness.

3 is may contribute to contractures and muscle weakness.

4 red to a trajectory of maintaining no muscle weakness.

5 use progressive debilitating focal extremity weakness.

6 eyes) had more than 9 clock hours of zonular weakness.

7 At discharge, 38% of patients had muscle weakness.

8 spinal cord, leading to fatally debilitating weakness.

9 gh myofilament Ca(2+)-sensitivity and muscle weakness.

10 n most dystrophinopathies is skeletal muscle weakness.

11 recommended to prevent or treat ICU-acquired weakness.

12 energy expenditure, slow walking speed, and weakness.

13 euronal positioning in the cortex and muscle weakness.

14 phragm fibrosis, a major cause of DMD muscle weakness.

15 ible for the disease-associated fatal muscle weakness.

16 r atrophy associated with muscle atrophy and weakness.

17 animals with this mutation display profound weakness.

18 ble to correct growth retardation and muscle weakness.

19 g with recurrent metabolic crises and muscle weakness.

20 gic examination, she reported subjective leg weakness.

21 characterized by chronic muscle wasting and weakness.

22 ill patients who do not develop ICU-acquired weakness.

23 n hyposialylation and the muscle atrophy and weakness.

24 204 included patients developed ICU-acquired weakness.

25 is characterised by muscle inflammation and weakness.

26 rized by muscle degeneration and progressive weakness.

27 dult-onset NM with slowly progressive muscle weakness.

28 multisystem disease with progressive muscle weakness.

29 ifesting with progressive muscle atrophy and weakness.

30 ss and can occur without preceding extremity weakness.

31 scle force and power in conditions of muscle weakness.

32 h neonatal or childhood hypotonia and muscle weakness.

33 ed by muscle failure leading to ICU-acquired weakness.

34 tory involvement without report of extremity weakness.

35 n devised, each with their own strengths and weaknesses.

36 sport, but its prevalence belies some of its weaknesses.

37 technique while offsetting their individual weaknesses.

38 each modeling approach has its strengths and weaknesses.

39 ests for Lassa fever and their strengths and weaknesses.

40 es of lipid nanodiscs while addressing their weaknesses.

41 life span, yet propose a theory with several weaknesses.

42 spin qubits, and each has its strengths and weaknesses.

43 se networks, each with its own strengths and weaknesses.

44 odel simulation, all with both strengths and weaknesses.

45 siological conditions in-vitro are intrinsic weaknesses.

46 rstanding of patient care seeking and system weaknesses.

47 re </=21 years old, with acute onset of limb weakness 1 August-31 December 2014 and spinal magnetic r

48 gia (53%), dysarthria (39%), and generalized weakness (37%).

49 Symptoms observed during admission included: weakness 74.7% (68); fever 70.8% (63/89); distress 63.7%

50 and functional deficits, most have residual weakness a year or more after onset.

51 ated a generalized slowly progressive muscle weakness accompanied by decreased vital capacities.

52 as a congenital myopathy with marked facial weakness and additional clinical and pathologic features

53 evaluate the association of post-ICU muscle weakness and associated trajectories of weakness over ti

54 Ca(2+) release channel (RyR1) display muscle weakness and atrophy, but the underlying mechanisms are

55 characteristics of progressive distal muscle weakness and atrophy, foot deformities, distal sensory l

56 opathies characterized by distal limb muscle weakness and atrophy.

57 nt hypermobility, joint contractures, muscle weakness and bone dysplasia as well as high myopia, with

58 -up the patient showed improvement of muscle weakness and carpopedal spasm with near-normal biochemic

59 se outcomes and describes a status of muscle weakness and decreased physiological reserve leading to

60 Muscle weakness and dizziness were more common in the combined-

61 characterized by progressive skeletal muscle weakness and dystrophic muscle exhibits degeneration and

62 n and treatment of rapidly progressive motor weakness and encephalopathy.

63 and lower motor neurons produces progressive weakness and eventually death.

64 rs often characterized by progressive muscle weakness and fragility.

65 ndividuals demonstrated improvement in motor weakness and functional deficits, most have residual wea

66 function is twice as frequent as limb muscle weakness and has a direct negative impact on weaning out

67 These mice display hindlimb weakness and impaired axonal conduction in sciatic nerve

68 s of skeletal muscle mass leads to prolonged weakness and less efficient rehabilitation.

69 -0.017 to -0.001, p=0.023) and with clinical weakness and lower MUNIX in multiple individual muscles.

70 es typically present with muscle wasting and weakness and may arise from pathology affecting the dist

71 tosis, and necrosis leading to severe muscle weakness and minimal postnatal growth.

72 delayed beyond infancy with proximal muscle weakness and most patients recall poor performance in sp

73 Muscle weakness and myopathy are observed in vitamin D deficien

74 osis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles.

75 hy characterized by ataxia, skeletal muscles weakness and numbness of the extremities in exposed huma

76 n he presented with acute-onset, right-sided weakness and numbness.

77 stis presented with acute-onset, right-sided weakness and numbness.

78 curs in many diseases and can lead to muscle weakness and premature muscle fatigue.

79 f improving muscle function in conditions of weakness and premature muscle fatigue.

80 Hypophosphatemia can lead to muscle weakness and respiratory and heart failure, but the mech

81 ith a history of progressive mild left-sided weakness and slowness of movements.

82 Weakness and slurred speech were the commonest presentat

83 ighlight what we feel are the main points of weakness and the types of evidence that could be provide

84 existence of these two forms of ICU-acquired weakness and their impact on outcome.

85 l involvement was associated with asymmetric weakness and urinary retention.

86 Muscular dystrophies are characterized by weakness and wasting of skeletal muscle tissues.

87 disease was indicated by muscle pain, muscle weakness and wasting, significant fat replacement of mus

88 tion of force, felt more effort and sense of weakness and were characterized by lower levels of optim

89 le for surgical chromophore application, the weaknesses and risks in each class of these compounds, a

90 d diaphragm dysfunction, 34% had limb muscle weakness, and 21% had both.

91 d weaning failure, 30.7% vs 23.8% had muscle weakness, and 90.9% vs 81.5% had hyperglycemia.

92 econdary infections, weaning failure, muscle weakness, and hyperglycemia (blood glucose level >150 mg

93 tudy amplitudes, more frequent occurrence of weakness, and later non-neuronal systemic involvement.

94 such as ptosis and ophthalmoplegia or facial weakness, and links myasthenic disorders with dystroglyc

95 s, including abdominal pain, fatigue, muscle weakness, and low plasma levels of selenium.

96 pectively, to pulmonary hypertension, muscle weakness, and sodium retention.

97 ngenital or early-onset hypotonia and muscle weakness, and specific pathological features on muscle b

98 rams and provides analysis of the strengths, weaknesses, and opportunities for the future.

99 approaches with complementary strengths and weaknesses, and the inclusion of a wider range of taxa a

100 icted effects include energy deficit, muscle weakness, anomalies in cranial and skeletal development,

101 riage and during hospitalization were fever, weakness, anorexia, and diarrhea, although 21% of patien

102 l muscle atrophy; persistent muscle loss and weakness are major complications that hamper recovery fr

103 uscle atrophy; persistent muscle atrophy and weakness are major complications that hamper recovery fr

104 The mechanisms underlying diaphragm weakness are unknown, but might include mitochondrial dy

105 Weaknesses are the limited assessment of the role of den

106 plications, each with distinct strengths and weaknesses, are available for distance-matrix based anal

107 e diseases with fluctuating fatigable muscle weakness as the clinical hallmark.

108 ys and consider their relative strengths and weaknesses as well as the technical limitations and pote

109 rved SC function and counteracted the muscle weakness associated with Duchenne-like dystrophy in the

110 d congenital or neonatal-onset hypotonia and weakness associated with mild-to-moderate facial and nec

111 [5.3%] of 114, P < .001), and severe muscle weakness at 4 weeks (Medical Research Council sum score,

112 Having weakness at discharge was associated with worse 5-year s

113 Neuromuscular weakness at the time of extubation was common in childre

114 se increase (five [1%]), colitis, and muscle weakness (both four [1%]).

115 In patients with post-ICU weakness, both persisting and resolving trajectories wer

116 While each approach has its strengths and weaknesses, both the SOM and the SSUM appear to be capab

117 sulting from defective rapsyn contributes to weakness, but is not solely responsible for use-dependen

118 isplayed significant atrophy and contractile weakness, but lacked impaired mitochondrial respiration

119 on by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diure

120 in activator, CK-2066260, counteracts muscle weakness by increasing troponin Ca(2+) affinity, thereby

121 One result of these weaknesses can be observed in the guidelines on safe sta

122 F1A2-deficient zebrafish had skeletal muscle weakness, cardiac failure and small heads.

123 ar-old male who came with symptoms of muscle weakness, carpopedal spasms and limitation of movement w

124 ef 4-item scale encompassing lower-extremity weakness, cognitive impairment, anemia, and hypoalbumine

125 atin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentr

126 creased in patients who develop ICU-acquired weakness compared with patients who do not develop ICU-a

127 y (BCVA), nuclear density, extent of zonular weakness, completeness of capsulotomy, and complications

128 synthetase (GARS), present with progressive weakness, consistently in the hands, but often in the fe

129 weight loss, skeletal muscle atrophy, muscle weakness, contractile abnormalities, the loss of functio

130 upper airway obstruction from oropharyngeal weakness contributes equally to an increased respiratory

131 ion, suggesting that quantitative BCR signal weakness contributes to restraint of IgE B cell response

132 uromuscular blocking agents and ICU-acquired weakness, critical illness polyneuropathy, and critical

133 ange, 0-60; higher is better), with post-ICU weakness defined as sum score less than 48.

134 characterized by severe, often fatal muscle weakness due to loss of motor neurons.

135 particularly susceptible to muscle loss and weakness during ageing, although how this is associated

136 acterized by exercise intolerance and muscle weakness even in the absence of sideroblastic anemia irr

137 the PFP characterized by the combination of weakness, exhaustion, and weight loss.

138 Recovery from ICU-acquired muscle weakness extends beyond hospital stay.

139 He had generalized muscle weakness, facial discomfort, recurrent episodes of carpo

140 with slowly progressive proximal and distal weakness, facial weakness, nasal speech, swallowing diff

141 ental status change (91%), at least 1 ocular weakness finding (84%), and neuroimaging without acute c

142 Respiratory muscle weakness frequently develops during mechanical ventilati

143 ary disorders characterized by hypotonia and weakness from birth with variable eye and central nervou

144 , grade 2 nausea, grade 2 generalised muscle weakness, grade 2 infection, grade 1 fever, and grade 1

145 te whether patients who develop ICU-acquired weakness have a different pattern of systemic inflammato

146 The two types of muscle weakness have only limited overlap.

147 d in the literature, but their strengths and weaknesses have never been compared on a common dataset.

148 ted ability to therapeutically exploit their weaknesses, have been limiting factors in realizing the

149 She reported additional symptoms of weakness, headache, and arthralgia primarily involving h

150 ary disease and intensive care unit-acquired weakness (ICUAW).

151 NALE: The clinical significance of diaphragm weakness in critically ill patients is evident: it prolo

152 Tongue weakness, like all weakness in Duchenne muscular dystrophy (DMD), occurs as

153 der tension was likely due to methodological weakness in early chromatin immunoprecipitation studies.

154 ed to amelioration of the muscle atrophy and weakness in Gne mutant mice.

155 Long-term weakness in ICU survivors results from heterogeneous mus

156 that this contributes to age-related muscle weakness in mammals, including humans.

157 heir dysfunctional conduction akin to muscle weakness in multiple sclerosis.

158 ore tested whether ActRIIB-mFc could improve weakness in NM mice through myofiber hypertrophy.

159 hat volume is one factor contributing to SAC weakness in oocytes.

160 ytokines is a potential biomarker for muscle weakness in OPMD.

161 ver therapy for intensive care unit acquired weakness in patients.

162 to previous research results, and avoidable weakness in research design, conduct and analysis.

163 strategy to combat skeletal muscle loss and weakness in stroke patients.

164 manifest diaphragm muscle fiber atrophy and weakness in the absence of mitochondrial dysfunction and

165 ed by pouches (that is, diverticulae) due to weakness in the bowel wall, which can become infected an

166 ith patients who do not develop ICU-acquired weakness in the first 4 days after ICU admission.

167 Muscular weakness in the first year after transplantation explain

168 One weakness in vitiligo management is the lack of an assess

169 nt myasthenic syndrome is characterized by a weakness in voluntary muscle contraction, a direct conse

170 hs because the effect is attenuated by other weaknesses in care.

171 ather or, alternatively, is a consequence of weaknesses in current forecast systems.

172 These in turn illustrate weaknesses in current treatment regimens and national tu

173 If diseases in nature arise because of weaknesses in holobiont physiology, instead of the virul

174 ency, but specific methodological issues and weaknesses in reporting exist.

175 Finally, common weaknesses in statistical analyses are considered.

176 h virus-host conflicts can point to possible weaknesses in the arsenal of viruses and may lead to the

177 We observed common study design and weaknesses in the methods, which substantially reduced t

178 mptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0.5-1.0% a

179 Weakness induced by critical illness (intensive care uni

180 However, a major weakness inherent to multiplex enzyme-linked immunosorbe

181 There was mild left-sided weakness involving the upper and lower limbs (medical re

182 ICU-acquired weakness is a common complication of critical illness an

183 Although respiratory muscle weakness is a known predictor of poor prognosis, a compr

184 In peripheral lesions, diaphragmatic weakness is a main element, but in many neuromuscular di

185 nt for cardiomyopathy and respiratory muscle weakness is advocated because early treatment may mitiga

186 her myasthenic syndromes, the general muscle weakness is also accompanied by use-dependent fatigue.

187 romuscular disease in which crippling muscle weakness is evident from birth.

188 Its weakness is its low sensitivity towards contrast media.

189 itical illness (intensive care unit acquired weakness) is a major cause of disability in patients and

190 lop therapy for intensive care unit acquired weakness, it was necessary to determine the mechanism un

191 Tongue weakness, like all weakness in Duchenne muscular dystrop

192 ciated with clinical complaints (arthralgia, weakness, loss of vitality, and being diabetic) and majo

193 IVIG and related to clinical outcome: muscle weakness (measured by Medical Research Council sum score

194 U scores among patients without ICU-acquired weakness (Medical Research Council sum score, >/= 48 vs

195 Fasciculation without weakness, muscle atrophy or increased tendon reflexes su

196 terized by higher proportions of arthralgia, weakness, myalgia, and age 41-60 years.

197 ressive proximal and distal weakness, facial weakness, nasal speech, swallowing difficulties, and nor

198 influence from mantle convection or crustal weakness necessary.

199 ns, which may explain some aspects of muscle weakness observed in patients with hypophosphatemia.

200 Facial weakness occurred in 50% of seropositive participants wh

201 sisting and resolving trajectories of muscle weakness, occurring in 50% of patients during follow-up,

202 igher in patients who developed ICU-acquired weakness (odds ratio, 1.35 [95% CI, 1.18-1.55]).

203 le-induced state is however weak, suggesting weakness of charge transfer (CT) effect and Mott insulat

204 We hypothesized that weakness of diaphragm muscle fibers in critically ill pa

205 "mating trait." This method sidesteps a key weakness of empirical studies, which lack an appropriate

206 t 8 months showed motor dysfunctions such as weakness of hind-limb and gait abnormality in an age-dep

207 etic inertness of C-C bonds and the relative weakness of newly formed carbon-metal bonds.

208 Insufficient quality control is a present weakness of passive sampling in water.

209 tal muscle disease characterized by muscular weakness of proximal dominance, hypotonia, and respirato

210 The easterly burst and the weakness of subsequent WWBs resulted in the persistence

211 to the explosive properties of K4Xe3O12: the weakness of supramolecular interactions allows to consid

212 n the development of atrophy and contractile weakness of the diaphragm in critically ill patients.

213 The weakness of the fluctuations indicates they might not be

214 However, due to the rarity of antimatter and weakness of the gravitational forces, the WEP has never

215 lization of the pi system of triplet O2, the weakness of the O-O sigma bond makes reactions of O2, wh

216 However, the guidelines also acknowledge the weakness of the supporting evidence.

217 ropy alloy compositions by demonstrating the weakness of this connection, the concept is overturned.

218 developed in utero- or neonatal-onset muscle weakness of variable severity.

219 n addition to highlighting the strengths and weaknesses of all of the PA-PB1 heterodimerization inhib

220 f other agencies, analyzes the strengths and weaknesses of American Heart Association peer review pra

221 Our findings highlight strengths and weaknesses of available bioinformatic tools for investig

222 n fission yeast and beyond, and it pinpoints weaknesses of commonly used auxotroph mutants for invest

223 ic liver disease, highlighting strengths and weaknesses of current and emergent approaches.

224 summary provides a view of the strengths and weaknesses of current technologies, provides perspective

225 ed to aid understanding of the strengths and weaknesses of different approaches, provide a mechanism

226 By scenario analysis, strengths and weaknesses of different measures were identified.

227 Our analysis points to the strengths and weaknesses of each of the currently available methods an

228 We discuss the strengths and weaknesses of each of the primary mechanisms proposed to

229 key questions, as well as the strengths and weaknesses of each option.

230 ere, we compare the individual strengths and weaknesses of each technique by imaging a variety of dif

231 A thorough appreciation of the strengths and weaknesses of each technique is critical when choosing t

232 e developments and discuss the strengths and weaknesses of live-cell imaging with antibody-based prob

233 antidepressant literature: the strengths and weaknesses of meta-analyses; the scientific and regulato

234 ng research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor ph

235 Identifying strengths and weaknesses of practice guidelines by ad hoc assessments

236 IGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses

237 ing findings and assessing the strengths and weaknesses of SAOMs when applied to animal rather than h

238 ore generally, we discuss some strengths and weaknesses of scientific methods that investigate quanti

239 Long-read sequencing can overcome the weaknesses of short reads in the assembly of eukaryotic

240 We highlight the strengths and weaknesses of some of the models proposed in H-NS-mediat

241 Weaknesses of the animal GVHD models include the irradia

242 and critical appraisal of the strengths and weaknesses of the cardiovascular health construct in chi

243 roscopy and then discusses the strengths and weaknesses of the different transparent window vibration

244 ation summaries presenting the strengths and weaknesses of the evidence in terms of benefits and harm

245 We highlight the strengths and weaknesses of the research methodology and reporting to

246 y Ebola response to reflect on strengths and weaknesses of the response.

247 We summarize the strengths and weaknesses of the three major approaches to characterizi

248 esearchers need to be aware of strengths and weaknesses of their data before they venture into furthe

249 ed reports, an overview of the strengths and weaknesses of these validation efforts, and a discussion

250 ation, with the aim to show that the earlier weaknesses of this concept have been addressed successfu

251 s; our analyses illustrate the strengths and weaknesses of this design.

252 previous critiques and identify fundamental weaknesses of this perspective, and provide brief compar

253 This Review discusses the strengths and weaknesses of three main approaches: transition-metal-ca

254 It begins by describing the strengths and weaknesses of today's diagnostics technologies in order

255 ffectively balance between the strengths and weaknesses of traditional models of aging.

256 n this Review, we describe the strengths and weaknesses of widely used computational approaches, expl

257 y (81%) or febrile (64%) illness before limb weakness onset.

258 ve also been explained using SWOT (Strength, Weakness, Opportunities, Threats) analysis.

259 by the sudden uncontrollable onset of muscle weakness or paralysis during wakefulness.

260 scle weakness and associated trajectories of weakness over time with 5-year survival.

261 itution did not correlate with resolution of weakness, owing to persistent impaired voluntary contrac

262 tor neurons, resulting in progressive muscle weakness, paralysis, and death within 5 years of diagnos

263 protein 2 is down-regulated in ICU-acquired weakness patients and mice with inflammation-induced mus

264 pathways enriched in muscle of ICU-acquired weakness patients, a gene set enrichment analysis of our

265 vation in vastus lateralis from ICU-acquired weakness patients.

266 regulated in skeletal muscle of ICU-acquired weakness patients.

267 Weakness persisted to 6 months and correlated with decre

268 The mechanisms responsible for long-term weakness persistence versus resolution are unknown.

269 To address such weakness, post-processing of stacked images is reported.

270 ta = .114, P = .009), and self-reported hand weakness (r = 0.243, beta = 0.203, P < .001) as independ

271 t lack of knowledge, skills, infrastructural weaknesses, reimbursement policies and communication wit

272 Deciphering mechanisms of muscle weakness requires sophisticated force protocols, dissect

273 In seven cases, severe muscle weakness resulted in death during the third trimester or

274 ciated with mild-to-moderate facial and neck weakness, significant neonatal-onset respiratory and swa

275 pathies associated with progressive muscular weakness that are characterized by the presence of desmi

276 any cases of NM and may represent a cause of weakness that can be counteracted by treatment.

277 nction (VIDD) refers to the diaphragm muscle weakness that occurs following prolonged controlled mech

278 rimental research methods have strengths and weaknesses that are largely complementary.

279 self-improver algorithm that fixes potential weaknesses that opponents have identified in the bluepri

280 Importance: Muscle weakness, the most common symptom of neuromuscular disea

281 or response criteria and their strengths and weaknesses, thus assisting radiologists in response asse

282 ls of these markers showed that ICU-acquired weakness was associated with an independent 1.5- to two-

283 ICU and hospital mortality, and limb muscle weakness was associated with longer duration of MV and h

284 Limb muscle weakness was defined as a Medical Research Council (MRC)

285 ptoms in children with botulism; generalized weakness was described more than paralysis.

286 ICU-acquired weakness was diagnosed by manual muscle strength testing

287 Muscle weakness was generally milder than observed in limb gird

288 In some cases, the weakness was severely disabling.

289 To overcome this weakness, we propose Fuse, a new multiple network alignm

290 To address this weakness, we propose the Cascading Alternating Renewal P

291 taracts of at least 6 clock hours of zonular weakness were included in the study.

292 her the two have complementary strengths and weaknesses, which synergize when combined to sharpen gen

293 myasthenic syndrome exhibit fatigable muscle weakness with a variety of accompanying phenotypes depen

294 last decade considering their strengths and weakness with an emphasis on miRNA biosensors.

295 All patients had prominent limb-girdle weakness with minimal or absent craniobulbar manifestati

296 acterised by various forms/degrees of muscle weakness with most cases being severe and resulting in d

297 laccid myelitis refers to acute flaccid limb weakness with spinal cord gray matter lesions on imaging

298 A weakness with this approach arises when melting overhang

299 wledge (BD2K) training program strengths and weaknesses with an eye toward future directions aimed at

300 VT in a patient with progressing lower limb weakness without any history or imaging findings of trau